benefits of glp-1 medications for weight loss Part 3 a 3-Part Series; GLP-1 Medications and Heart Health

Lower concentrations reduce injection volume but require more frequent refrigerator access, increasing temperature fluctuation risk

Mineralocorticoid receptor antagonists MRAs act by preventing aldosterone binding to mineralocorticoid receptors

Urolithin A supports mitochondrial function and muscle health

In one Phase 2 trial of people with obesity, called VISTA, those on the highest dose of the drug, called elecoglipron, lost 11.2% of their weight after 36 weeks, when looking at all patients regardless of discontinuations, according to data presented Monday at the annual meeting of the American Diabetes Association and published in the Lancet

What role does hydration play in managing adrenal fatigue in functional medicine